291 related articles for article (PubMed ID: 28146604)
1. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
Ahmad A; Olah G; Herndon DN; Szabo C
Br J Pharmacol; 2018 Jan; 175(2):232-245. PubMed ID: 28146604
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Ahmad A; Haas De Mello A; Szczesny B; Törö G; Marcatti M; Druzhyna N; Liaudet L; Tarantini S; Salomao R; Garcia Soriano F; Szabo C
Shock; 2020 May; 53(5):653-665. PubMed ID: 31274831
[TBL] [Abstract][Full Text] [Related]
3. Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury.
Ahmad A; Herndon DN; Szabo C
Burns; 2019 May; 45(3):671-681. PubMed ID: 31018913
[TBL] [Abstract][Full Text] [Related]
4. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.
Korkmaz-Icöz S; Szczesny B; Marcatti M; Li S; Ruppert M; Lasitschka F; Loganathan S; Szabó C; Szabó G
Br J Pharmacol; 2018 Jan; 175(2):246-261. PubMed ID: 28806493
[TBL] [Abstract][Full Text] [Related]
5. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Ghonim MA; Pyakurel K; Ibba SV; Al-Khami AA; Wang J; Rodriguez P; Rady HF; El-Bahrawy AH; Lammi MR; Mansy MS; Al-Ghareeb K; Ramsay A; Ochoa A; Naura AS; Boulares AH
J Transl Med; 2015 Jul; 13():225. PubMed ID: 26169874
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
Sahu B; Narota A; Naura AS
Eur J Pharmacol; 2020 Jun; 877():173091. PubMed ID: 32234526
[TBL] [Abstract][Full Text] [Related]
8. Effect of 3-mercaptopyruvate Sulfurtransferase Deficiency on the Development of Multiorgan Failure, Inflammation, and Wound Healing in Mice Subjected to Burn Injury.
Ahmad A; Druzhyna N; Szabo C
J Burn Care Res; 2019 Feb; 40(2):148-156. PubMed ID: 30649358
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Liu W; Ren X; Wang Q; Zhang Y; Du J
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
[TBL] [Abstract][Full Text] [Related]
10. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Dharwal V; Naura AS
Biochem Pharmacol; 2018 Apr; 150():24-34. PubMed ID: 29355504
[TBL] [Abstract][Full Text] [Related]
11. Both the H
Ahmad A; Szabo C
Pharmacol Res; 2016 Nov; 113(Pt A):348-355. PubMed ID: 27639598
[TBL] [Abstract][Full Text] [Related]
12. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger NA; Besson VC; Boulares AH; Bürkle A; Chiarugi A; Clark RS; Curtin NJ; Cuzzocrea S; Dawson TM; Dawson VL; Haskó G; Liaudet L; Moroni F; Pacher P; Radermacher P; Salzman AL; Snyder SH; Soriano FG; Strosznajder RP; Sümegi B; Swanson RA; Szabo C
Br J Pharmacol; 2018 Jan; 175(2):192-222. PubMed ID: 28213892
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Kapoor K; Singla E; Sahu B; Naura AS
Mol Cell Biochem; 2015 Feb; 400(1-2):153-62. PubMed ID: 25404465
[TBL] [Abstract][Full Text] [Related]
14. Cystathionine-gamma-lyase deficient mice are protected against the development of multiorgan failure and exhibit reduced inflammatory response during burn.
Ahmad A; Druzhyna N; Szabo C
Burns; 2017 Aug; 43(5):1021-1033. PubMed ID: 28318752
[TBL] [Abstract][Full Text] [Related]
15. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.
Kovacs K; Vaczy A; Fekete K; Kovari P; Atlasz T; Reglodi D; Gabriel R; Gallyas F; Sumegi B
Invest Ophthalmol Vis Sci; 2019 Apr; 60(5):1478-1490. PubMed ID: 30973576
[TBL] [Abstract][Full Text] [Related]
17. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
18. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
19. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic aspects of inducible nitric oxide synthase-induced lung injury in burn trauma.
Enkhbaatar P; Wang J; Saunders F; Lange M; Hamahata A; Rehberg S; Parkinson JF; Traber LD; Herndon DN; Traber DL
Burns; 2011 Jun; 37(4):638-45. PubMed ID: 21334141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
